EUCTR2019-004942-14-BE进行中（未招募）1 期
eoadjuvant study of targeting ROS1 in combination with endocrine therapy in invAsive Lobular carcINoma of the breast
Institut Jules Bordet0 个研究点目标入组 50 人开始时间: 2020年10月15日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •2.Age = 18 years
- •3.Histological diagnosis of invasive lobular breast adenocarcinoma that is ER+, and HER2- as per the updated American Society of Clinical Oncology (ASCO) - College of American Pathologists (CAP) guidelines according to local testing.
- •4.Multifocal unilateral or bilateral breast adenocarcinoma tumours are allowed if all tested foci are lobular, ER+ and HER2-.
- •oER positive (ER+ is defined as having an IHC of 1% or more and/or an Allred of 3 or more and HER2-).
- •oHER2 negative (HER2- is defined as having an IHC of 0 or 1+ without ISH OR IHC 2+ and ISH non-amplified with ratio less than 2.0 and if reported, average HER2 copy number < 4 signals/cells OR ISH non-amplified with ratio less than 2.0 and if reported, average HER2 copy number < 4 signals/cells [without IHC]);
- •5.A primary non metastatic or locally advanced tumour of more than 20 mm as measured by breast MRI, cN0 or cN1 without prior treatment candidate for preoperative treatment.
- •6.ECOG Performance Status (PS) 0 or 1.
- •7.Adequate Bone Marrow Function including:
- •oAbsolute Neutrophil Count (ANC) =1500/µL or =1.5x109/L;
- •oPlatelets =100000/µL or =100 x 109/L;
- •oHaemoglobin = 9 g/dL.
- •8.Adequate Renal Function including:
- •oSerum creatinine = 1.5 x upper limit of normal (ULN) or estimated creatinine clearance = 60 ml/min as calculated using the method standard for the institution.
- •9.Adequate Liver Function, including all of the following parameters:
- •oTotal serum bilirubin = 2.0 x ULN unless the subject has documented Gilbert syndrome
- •oAspartate and Alanine Aminotransferase (AST and ALT) = 3 x ULN;
- •10.Signed Informed Consent form (ICF) obtained prior to any study related procedure.
- •11.Completion of all necessary screening procedures within 28 days prior to enrolment. Biopsies at screening must have been obtained up to max 6 weeks before the beginning of treatment.
- •12.Subject is willing and able to comply with the protocol for the duration of the study including treatment and scheduled visits and examinations.
- •13.Women who are not postmenopausal or have not undergone hysterectomy must have documented negative pregnancy test (serum) within 28 days prior to enrolment.
- •14.Women of childbearing potential and their partners, who are sexually active, must agree to use one highly effective form of contraception (see protocol section 6.6.1) from the signing of the ICF until at least 5 weeks after last administration of entrectinib, or they must totally/truly abstain from any form of sexual intercourse. Use of oral hormonal contraceptive agents in this study is not permitted.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 13
排除标准
- •Subjects who exhibit any of the following conditions at screening will not be eligible for admission into the study.
- •1.Clinical T4 disease including inflammatory breast cancer and/or cN2 or cN3.
- •2.Prior history of invasive cancer in the past 5 years except basal or squamous cell carcinoma of skin that has been definitively treated.
- •3.Known hypersensitivity to the study drugs or excipients.
- •4.Hyperuricemia > Grade 1
- •5.Any illness or medical condition that is unstable or could jeopardize the safety of the subject or her compliance with study requirements.
- •6.Subjects unable to swallow oral medications.
- •7.Prior intake of letrozole, any ROS1 inhibitor, any TRK inhibitor or anticancer therapy (including endocrine therapy).
- •8.Concurrent treatment with strong or moderate CYP3A inhibitor.
- •9.Concurrent treatment with any of the drugs not permitted, i.e. strong CYP3A inducers and drugs known to cause QTc interval prolongation.
- •10.Significant cardiac disease, including recent (less than 6 months) myocardial infarction, congestive heart failure, unstable angina, and bradyarrhythmias.
- •11.LVEF = 55% measured by ECHO or MUGA (ECHO should be the preferred method)
- •12.QTc exceeding 450 msec, history of prolonged QTc interval prolongation; risk factors for torsade de pointes; other concomitant medications that may prolong QTc; family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes (TdP); uncorrected electrolyte imbalances
- •13.Pregnant or lactating women.
- •14.Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis
- •15.Peripheral neuropathy = Grade 2
- •16.Active gastrointestinal disease (e.g., Crohn’s disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would reasonably impact drug absorption.
研究者
相似试验
进行中（未招募）
2 期
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)Invasive Lobular Breast CarcinomaER+ Breast CancerHER2-negative Breast CancerNCT04551495Jules Bordet Institute65
尚未招募
不适用
Incidence of Gene mutation in Lung CancerCTRI/2017/07/009024Tata Memorial center
进行中（未招募）
1 期
Phase II study of crizotinib and Fluvestrant in lobular breast cancer or diffuse gastric cancerEUCTR2017-001680-20-GBRoyal Marsden Hospital58
已完成
2 期
Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid TumoursLobular Breast CarcinomaGastric CancerTriple Negative Breast CancerCDH1 Gene MutationNCT03620643Royal Marsden NHS Foundation Trust33
已完成
不适用
Feasibility of adjuvant treatment with S-1 and oxaliplatin in patients with resectable esophageal canceresophageal cancerNL-OMON47475Academisch Medisch Centrum40